Nicotinum shortage — IS supply status & alternatives

Nicotinum

—

In supply · Australia

Nicotinell Mint

In supply · 🇦🇺 Australia · short in🌐 IS

In supply in Australia

Reading today’s signals…

✓ Can I substitute?

In supply

no shortage substitution needed

⇄ Best alternative

None listed

refer to prescriber

◷ Expected back

No estimate

No estimate provided

Product attributes reference data we hold

Active ingredient (INN)	Nicotinum
Brand names	Nicotinell Mint
Therapeutic category	Auto-created by Lyfjastofnun — Tilkynntur lyfjaskortur (Iceland Medicines Agency) scraper
Controlled substance	No

Registrations on file	3

Patient information leaflet (PIL)	Not on file

Summary of product characteristics (SPC)	Not on file

Trade price 🇦🇺 Australia · awaiting price ingest

🇦🇺 AU

Ex-manufacturer

—

Dispensed (DPMQ)

—

Pack

—

Not yet captured for Australia

Official pricing isn’t on file for this market yet. PBS (Australia), NHS Drug Tariff (United Kingdom) and CMS NADAC (United States) feeds are prioritised; this panel populates automatically once the data lands.

Substitution pathways 🇦🇺 Australia · TGA

—

No substitution instrument in force

Dispense per normal rules, or refer to the prescriber. No active SSSI/S19A instrument detected for this medicine.

Verified timeline regulator events

🌐 26 June 2026

medium reported

🌐 24 June 2026

Shortage resolved

🌐 15 June 2026

medium reported

🌐 30 Apr 2026

medium reported

🌐 22 Apr 2026

Shortage resolved

🌐 25 Mar 2026

Shortage resolved

Registration recordmarketing-authorisation holders

Registrations & marketing-authorisation holders3 registrations · 2 MA holders

Product	Strength	Form	Market	MA holder	Status
Nicotinum	30[hp_C]/30[hp_C]	pellet	🇺🇸 US	BOIRON	Active
NICOTINUM	200[kp_C]/200[kp_C]	pellet	🇺🇸 US	BOIRON	Active
NICOTINUM	—	granules	🇨🇦 CA	DOLISOS CANADA INC.	Cancelled

For health-professional reference only. Mederti aggregates shortage and substitution information from official regulatory sources. It is not clinical advice and data may be incomplete or delayed. Confirm any substitution or supply decision against the primary regulator source, the prescriber, and current clinical references (e.g. AMH) before acting. Terms.